US imposes 100% tariff on imported patented pharmaceuticals, targeting Australia and global exporters
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals imported into the US, effective July 31, 2025, targeting global exporters including Australia. The move, enacted under Section 232 of the Trade Expansion Act, bypasses a February Supreme Court ruling that struck down Trump’s broader ‘Liberation Day’ tariffs. Australia, which exported $1.32 billion in pharmaceuticals to the US in 2025, faces potential disruptions, though key exporter CSL may qualify for exemptions due to its US manufacturing facilities and plasma-derived therapies. The tariff incentivizes companies to relocate production to the US, offering reduced rates (20%) or zero tariffs for those securing ‘most favoured nation’ drug pricing deals. Countries like the EU, Japan, and the UK have negotiated lower tariffs (10-15%), while Australia lacks a special deal. Health Minister Mark Butler emphasized Australia’s refusal to alter its subsidized Pharmaceutical Benefits Scheme (PBS), which keeps drug prices lower than in the US—a policy Trump’s administration has criticized. Opposition Leader Angus Taylor pledged bipartisan efforts to secure exemptions or overturn the tariffs. The move reflects Trump’s broader push to reshoring pharmaceutical production, citing national security concerns over supply chain dependencies.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order imposing a 100% tariff on patented pharmaceuticals manufactured outside the US, effective July 31, 2025, under Section 232 of the Trade Expansion Act (NEWSCOMAU, SMH, THEAGE, GUARDIAN, ABC).
- Australia exported $US1.32 billion ($1.91 billion AUD) worth of pharmaceuticals to the US in 2025 (NEWSCOMAU, ABC).
- CSL, a Melbourne-based company, manufactures the bulk of Australia’s pharmaceutical exports to the US, with significant US-based production facilities in Illinois and North Carolina (NEWSCOMAU, SMH, THEAGE, GUARDIAN, ABC).
- CSL’s plasma-derived therapies (used for rare autoimmune diseases and blood-clotting disorders) may be exempt from tariffs if they meet an ‘urgent US health need’ or if Australia negotiates a trade deal with the US (NEWSCOMAU, SMH, THEAGE).
- The US Supreme Court ruled in February 2025 that Trump’s ‘Liberation Day’ tariffs were illegal, but the pharmaceutical tariffs were enacted under different legislation and are unaffected (NEWSCOMAU, SMH, THEAGE, ABC).
- Companies moving production to the US can reduce tariffs to 20%, and those securing ‘most favoured nation’ drug pricing deals could face zero tariffs (NEWSCOMAU, SMH, THEAGE, GUARDIAN, ABC).
- Japan, EU, South Korea, Switzerland, and Liechtenstein have negotiated 15% tariffs on their pharmaceutical exports to the US, while the UK secured a 10% tariff (NEWSCOMAU, SMH, THEAGE).
- CSL announced a $US2.2 billion (or $US1.5 billion in other sources) expansion of its Illinois factory in March 2025, with completion set for 2031 (NEWSCOMAU, SMH, THEAGE).
- Australia’s Pharmaceutical Benefits Scheme (PBS) subsidizes drug prices, making them cheaper for Australians than in the US—a policy Trump’s administration has criticized as undermining ‘most favoured nation’ pricing rules (NEWSCOMAU, SMH, THEAGE, GUARDIAN).
- Health Minister Mark Butler stated Australia would not negotiate changes to the PBS, calling it ‘fundamental’ to Australia’s healthcare system (NEWSCOMAU, SMH, THEAGE, GUARDIAN).
- Opposition Leader Angus Taylor pledged to work with the government to overturn the tariffs or secure exemptions for Australian exporters (NEWSCOMAU, SMH, THEAGE, GUARDIAN).
- Large pharmaceutical companies have 120 days to announce re-shoring plans or pricing deals to avoid the 100% tariff, while smaller firms have 180 days (SMH, ABC).
- The tariffs apply only to patented drugs, not generic medicines (NEWSCOMAU, ABC)
Points of Difference
Details reported by only one source:
- The tariff applies to patented products only, not generic medicines (explicitly stated).
- Mark Butler mentioned ‘subsidised Australian prices under the Pharmaceutical Benefits Scheme’ would not rise, but the US has been critical of this scheme.
- The US Supreme Court ruling in February specifically invalidated Trump’s ‘liberation day’ tariffs, but the pharmaceutical tariffs were enacted under Section 232 of the Trade Expansion Act.
- A White House official stated pharmaceutical companies could make deals with the White House to lower US prices and avoid any levy.
- The tariff on steel components was adjusted: if a product has less than 15% steel, the additional tariff is set to zero; if it exceeds 15%, the steel tariff is 25% on the total value.
- The tariff announcement was timed to mark one year since Trump’s ‘Liberation Day’ tariffs (February 2025).
- A White House official said Australia does not have a ‘special pharma tariff rate’ despite being a close ally.
- The text of Trump’s executive order explicitly states the tariff would be set to zero for plasma-derived therapies if they come from a country with a current or forthcoming trade deal with the US or meet an urgent US health need.
- The US Commerce Department has discretion to grant exemptions to companies like CSL, which must submit their re-shoring plans for review.
- No additional unique details beyond SMH and NEWSCOMAU; identical to SMH’s reporting.
- Communications Minister Anika Wells stated the Australian PBS is ‘not for sale’ and ‘world leading,’ emphasizing the government’s refusal to compromise on drug pricing.
- The Guardian explicitly notes that American consumers pay far more for prescription medicines than Australians due to the PBS, which is a source of frustration for Trump.
- A senior administration official stated that too many drugs ‘driven by research and development in the US’ are now produced abroad, making the US ‘beholden to these other countries.’
- Trump previously suggested the tariff could be as high as 200% (in September 2024), but it was ultimately set at 100%.
- CSL’s social media post in September 2024 stated it did not expect any material impact from the tariff’s implementation, despite earlier warnings.
- The tariff is being implemented under national security powers to ensure a secure supply of vital drugs during global conflicts or emergencies like pandemics.
- Health Minister Mark Butler called the decision 'deeply disappointing and deeply concerning' (no additional details).
Contradictions
Conflicting information between sources:
- NEWSCOMAU and ABC report CSL’s US factory expansion as $US2.2 billion, while SMH and THEAGE report it as $US1.5 billion.
- NEWSCOMAU states the tariff applies to patented products only, but ABC does not explicitly mention this distinction.
- SMH and THEAGE state the tariff is set to zero for plasma-derived therapies if they come from a country with a current or forthcoming trade deal with the US, while NEWSCOMAU states it applies if they meet an ‘urgent US health need’—both conditions are mentioned but not clearly reconciled.
- ABC reports Trump previously suggested the tariff could be as high as 200%, but this is not mentioned in other sources as a past statement.
- NEWSCOMAU and SMH mention the US Supreme Court ruling in February 2025 invalidated Trump’s ‘Liberation Day’ tariffs, but ABC does not explicitly state the date of the ruling, only that it was in February.
Source Articles
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....